AbCellera Biologics Inc.
ABCL
Rang în acțiuni
#4143
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Preț acțiune
$11.99
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$3.88B
Schimbare (1 zi)
1.57%
Schimbare (1 an)
104.52%
Țară
CA
Tranzacționează AbCellera Biologics Inc. (ABCL)
Categorie
Healthcare
Raport P/B pentru AbCellera Biologics Inc. (ABCL)
Raport P/B la data de October 2026 TTM: 4.22
Conform celor mai recente rapoarte financiare și prețului acțiunilor AbCellera Biologics Inc., raportul P/B actual (TTM) este 4.22. La sfârșitul anului 2023, compania avea un P/B de 1.43.
Istoricul raportului P/B pentru AbCellera Biologics Inc. din 2018 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 4.22 | 414.44% |
| 2024 | 0.82 | -43.01% |
| 2023 | 1.43 | -38.80% |
| 2022 | 2.34 | -39.10% |
| 2021 | 3.84 | -70.56% |
| 2020 | 13.06 | -98.53% |
| 2019 | 885.28 | 15.51% |
| 2018 | 766.43 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | 48.18% |
US
|
|
| 13.2547 | 214.21% |
US
|
|
| 4.208 | -0.25% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 46.56% |
NL
|
